PhuturdexDrug Pipeline Intelligence
Try for free

Phuturdex › Drugs › Pumitamig

Drugs in development · updated 30 October 2026

Pumitamig: clinical trials and development status

FDA substance registryNot approved in the USNo EMA authorisationEstimated launch Mar 2030 – Jan 2031 (Phuturdex estimate)

As of 30 October 2026 Pumitamig is in 27 active clinical trials (recruiting or ongoing, phases I–III) for 22 diseases. The most advanced phase is III.

27Active trials
IIIMost advanced phase
22Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Pumitamig and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Non-small-cell lung carcinomaIII11NCT07361510
Lung neoplasmIII3NCT06712355
Lung small cell carcinomaIII3NCT06712355
Breast neoplasmIII2NCT07173751
Colorectal neoplasmII–III2NCT07221357
Stomach neoplasmII–III2NCT07221149
Esophagus adenocarcinomaII–III1NCT07221149
MelanomaII3NCT07492680
Renal cell carcinomaI–II3NCT07293351
Brain NeoplasmsII2NCT07297212
Pancreatic neoplasmII2NCT07492680
Triple-negative breast neoplasmI–II2NCT06618287
Autosomal dominant Parkinson disease 4I–II1NCT07147348
GlioblastomaII1NCT07297212
Head and neck squamous cell carcinomaI–II1NCT04895709
Hepatocellular carcinomaI–II1NCT07291076
NeoplasmI–II1NCT07079631
Ovarian neoplasmI–II1NCT04895709
Transitional cell carcinomaI–II1NCT04895709
Uterine cervix neoplasmI–II1NCT04895709
Clear-cell metastatic renal cell carcinomaI1NCT07195682
Kidney neoplasmI1NCT07195682

Everything on Pumitamig

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch